Intercell to slash Gaithersburg staff; Harvard spinout plans to become biomarker 'eBay;'

@FierceBiotech: Cell transplant gets paralyzed monkey back on his feet. Report | Follow @FierceBiotech 

 @JohnCFierce: FDA wants to encourage apps on combo drugs, using more lab/animal data in evaluations. That may work for cancer, but not for obesity, etc. | Follow @JohnCFierce

> The recent failure of Intercell's vaccine patch program is forcing the company to axe half of the old Iomai staff in Gaithersburg, MD. Iomai and its patch technology was acquired by Intercell. Report

> Bluebird bio and France's Généthon announced a research collaboration focused on process development and scale up efforts for the manufacturing of lentiviral vectors. bluebird release

> A fledgling Harvard spinout that styles itself as the future "eBay of biomarkers" has raised $3 million, according to a report in MassHighTech. This appears to be the first amount raised by GnuBio, which plans to pool a mountain of biological samples from institutes around the globe into a single, open-source platform. Item

> UK researchers are closing in on a new set of biomarkers for Huntington's disease which can be used by developers to set up new endpoints in future clinical trials. Story

> New and far more sensitive assays made it possible for a team of investigators in San Diego to propose a new biomarker that could be used to better evaluate a heart failure patient's chances of death or readmission. Story

And Finally... Michael J. Fox made an impassioned plea for more resources to back collaborative, open-source projects like PPMI and the Alzheimer's Disease Neuroimaging Initiative, which has also been focused on finding new biomarkers. Column

Suggested Articles

Eli Lilly is combining the oncology team at Lilly Research Laboratories with Loxo Oncology and putting a trio of Loxo execs at the helm.

The failure of SAGE-217 to beat placebo wiped more than 50% off Sage’s share price as investors digested the implications of the data.

The data tee Aurinia up to file for FDA approval next year and go on to address a major unmet medical need.